Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 14/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037317 | 1.00 | STING1 (0.49) | STING1ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL8620596 | 0.86 | STING1 (0.46) | STING1 | |
| SCHEMBL12729604 | 0.86 | STING1 (0.46) | STING1 | |
| SCHEMBL12352439 | 0.82 | STING1 (0.52) | STING1ALDH1A1MAPK1 | |
| SCHEMBL12595500 | 0.82 | STING1 (0.52) | STING1ALDH1A1MAPK1 | |
| SCHEMBL17772331 | 0.82 | STING1 (0.52) | STING1ALDH1A1MAPK1 | |
| SCHEMBL12222444 | 0.82 | STING1 (0.52) | STING1ALDH1A1MAPK1 | |
| SCHEMBL8624094 | 0.82 | STING1 (0.52) | STING1ALDH1A1MAPK1 | |
| SCHEMBL12729578 | 0.82 | STING1 (0.52) | STING1ALDH1A1MAPK1 | |
| SCHEMBL17860546 | 0.81 | STING1 (0.58) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190175633-A1 | REACTIVE, LIPOPHILIC NUCLEOSIDE BUILDING BLOCKS FOR THE SYNTHESIS OF HYDROPHOBIC NUCLEIC ACIDS | IONOVATION GMBH (DE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175633-A1 | REACTIVE, LIPOPHILIC NUCLEOSIDE BUILDING BLOCKS FOR THE SYNTHESIS OF HYDROPHOBIC NUCLEIC ACIDS | NCL, NOP2, HNRNPD | STING1 925/4885ALDH1A1 3589/4885LMNA 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.